Compare IPHA & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | AOMR |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 191.5M |
| IPO Year | 2014 | 2019 |
| Metric | IPHA | AOMR |
|---|---|---|
| Price | $1.43 | $5.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.67 | ★ $9.75 |
| AVG Volume (30 Days) | 17.5K | ★ 117.6K |
| Earning Date | 09-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 20.75% |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $390.56 | N/A |
| Revenue Next Year | $143.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $6.14 |
| 52 Week High | $2.71 | $9.30 |
| Indicator | IPHA | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 27.58 |
| Support Level | $1.38 | N/A |
| Resistance Level | $1.59 | $9.24 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 39.29 | 0.00 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.